The drug, ACI193, was well tolerated in the first trial testing it in people, the company said. Results of the randomised, placebo-controlled study of 62 patients with early Alzheimer’s disease were presented at the Alzheimer’s Association’s International Conference in Amsterdam., The drug, ACI193, was well tolerated in the first trial testing it in people, the company said. Results of the randomised, placebo-controlled study of 62 patients with early Alzheimer’s disease were presented at the Alzheimer’s Association’s International Conference in Amsterdam., , Read More
AAS Yoga
Go for Euphoria – Illness to Wellness the Natural Way